Immunotherapy for the Treatment of Breast Cancer

Brenda Ernst, Karen Anderson

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

Original languageEnglish (US)
JournalCurrent Oncology Reports
Volume17
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Immunotherapy
Breast Neoplasms
Cancer Vaccines
Neoplasm Antigens
Lung Neoplasms
Hematologic Neoplasms
Therapeutics
Innate Immunity
Dendritic Cells
Immunity
Melanoma
Neoplasms
Prostatic Neoplasms
Clinical Trials
Research

Keywords

  • Immunotherapy
  • Tumor antigen
  • Tumor immunology
  • Vaccine

ASJC Scopus subject areas

  • Oncology

Cite this

Immunotherapy for the Treatment of Breast Cancer. / Ernst, Brenda; Anderson, Karen.

In: Current Oncology Reports, Vol. 17, No. 2, 2015.

Research output: Contribution to journalArticle

@article{dd2dc9f343a141edaf805986f109bb6e,
title = "Immunotherapy for the Treatment of Breast Cancer",
abstract = "Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.",
keywords = "Immunotherapy, Tumor antigen, Tumor immunology, Vaccine",
author = "Brenda Ernst and Karen Anderson",
year = "2015",
doi = "10.1007/s11912-014-0426-9",
language = "English (US)",
volume = "17",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Immunotherapy for the Treatment of Breast Cancer

AU - Ernst, Brenda

AU - Anderson, Karen

PY - 2015

Y1 - 2015

N2 - Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

AB - Decades of research are now leading to therapeutics that target the molecular mechanisms of the cancer-specific immune response. These therapeutics include tumor antigen vaccines, dendritic cell activators, adjuvants that activate innate immunity, adoptive cellular therapy, and checkpoint blockade. The advances in targeted immunotherapy have led to clinical advances in the treatment of solid tumors such as melanoma, prostate cancer, lung cancer, and hematologic malignancies. Preclinical and translational studies suggest that patients with breast cancer may also benefit from augmenting effective immune responses. These results have led to early-phase clinical trials of tumor antigen vaccines, adjuvants, and combinations of checkpoint inhibitor blockade to boost breast cancer-specific immunity in patients. This review focuses on the current and emerging development of cancer immunotherapy for breast cancer.

KW - Immunotherapy

KW - Tumor antigen

KW - Tumor immunology

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84923087112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923087112&partnerID=8YFLogxK

U2 - 10.1007/s11912-014-0426-9

DO - 10.1007/s11912-014-0426-9

M3 - Article

VL - 17

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -